Vidarabine

"Vidarabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.

Descriptor ID	D014740
MeSH Number(s)	D03.633.100.759.590.138.900 D13.570.065.950 D13.570.583.138.900
Concept/Terms	Vidarabine Vidarabine beta-Ara A beta Ara A Adenine Arabinoside Arabinoside, Adenine alpha-D-Arabinofuranosyladenine alpha D Arabinofuranosyladenine Ara A alpha-Ara A alpha Ara A Arabinofuranosyladenine Arabinosyladenine 9-beta-D-Arabinofuranosyladenine 9 beta D Arabinofuranosyladenine 9-beta-Arabinofuranosyladenine 9 beta Arabinofuranosyladenine Ara-A Vira-A Vira-A Vira A ViraA

Below are MeSH descriptors whose meaning is more general than "Vidarabine".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
Purines [D03.633.100.759]
Purine Nucleosides [D03.633.100.759.590]
Adenosine [D03.633.100.759.590.138]
Vidarabine [D03.633.100.759.590.138.900]
Nucleic Acids, Nucleotides, and Nucleosides [D13]
Nucleosides [D13.570]
Arabinonucleosides [D13.570.065]
Vidarabine [D13.570.065.950]
Purine Nucleosides [D13.570.583]
Adenosine [D13.570.583.138]
Vidarabine [D13.570.583.138.900]

Below are MeSH descriptors whose meaning is related to "Vidarabine".

Below are MeSH descriptors whose meaning is more specific than "Vidarabine".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Vidarabine" by people in this website by year, and whether "Vidarabine" was a major or minor topic of these publications.

Bar chart showing 9 publications over 7 distinct years, with a maximum of 3 publications in 2005

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	0	1
2001	1	0	1
2003	1	0	1
2005	1	2	3
2008	0	1	1
2017	1	0	1
2018	0	1	1

Below are the most recent publications written about "Vidarabine" by people in Profiles.

Nemecek ER, Hilger RA, Adams A, Shaw BE, Kiefer D, Le-Rademacher J, Levine JE, Yanik G, Leung W, Talano JA, Haut P, Delgado D, Kapoor N, Petrovic A, Adams R, Hanna R, Rangarajan H, Dalal J, Chewning J, Verneris MR, Epstein S, Burroughs L, Perez-Albuerne ED, Pulsipher MA, Delaney C. Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. Biol Blood Marrow Transplant. 2018 08; 24(8):1651-1656.

View in: PubMed
Ghanem KM, Kharfan-Dabaja MA, El-Solh H, Harris N, Kreidieh N, Nehme R, Muwakkit SA, Saab R, Bazarbachi A, Abboud MR. Fludarabine-based reduced intensity regimen for matched related donor hematopoietic stem cell transplantation in acquired severe aplastic anemia. Curr Res Transl Med. 2017 09; 65(3):115-119.

View in: PubMed
Hainsworth JD, Vazquez ER, Spigel DR, Raefsky E, Bearden JD, Saez RA, Greco FA. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer. 2008 Mar 15; 112(6):1288-95.

View in: PubMed
Srinivasan S, Ito M, Kajiya H, Key LL, Johnson-Pais TL, Reddy SV. Functional characterization of human osteoclast inhibitory peptide-1 (OIP-1/hSca) gene promoter. Gene. 2006 Apr 12; 371(1):16-24.

View in: PubMed
Kasamon YL, Flinn IW, Grever MR, Diehl LF, Garrett-Mayer E, Goodman SN, Lucas MS, Byrd JC. Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. Clin Cancer Res. 2005 Dec 01; 11(23):8413-7.

View in: PubMed
McLaughlin P, Estey E, Glassman A, Romaguera J, Samaniego F, Ayala A, Hayes K, Maddox AM, Preti HA, Hagemeister FB. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood. 2005 Jun 15; 105(12):4573-5.

View in: PubMed
Frankel AE, Fleming DR, Hall PD, Powell BL, Black JH, Leftwich C, Gartenhaus R. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3555-61.

View in: PubMed
Carbone GM, Catapano CV, Fernandes DJ. Imbalanced DNA synthesis induced by cytosine arabinoside and fludarabine in human leukemia cells. Biochem Pharmacol. 2001 Jul 01; 62(1):101-10.

View in: PubMed
Li L, Liu X, Glassman AB, Keating MJ, Stros M, Plunkett W, Yang LY. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res. 1997 Apr 15; 57(8):1487-94.

View in: PubMed
Whitley RJ, Gnann JW, Hinthorn D, Liu C, Pollard RB, Hayden F, Mertz GJ, Oxman M, Soong SJ. Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group. J Infect Dis. 1992 Mar; 165(3):450-5.

View in: PubMed

People

Explore

Similar Concepts

Top Journals